The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity

Journal of Leukocyte Biology

Volumn 95, Issue 2, 2014, Pages 337-345

  Kim, Hyun Ju ^a   Yoon, Hye Jin ^a   Choi, Je Yong ^a,b   Lee, In Kyu ^b   Kim, Shin Yoon ^a,b  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

C Fms; C Fos; lPS; NF B; Osteoporosis

Indexed keywords

ACTIN; BIM PROTEIN; CASPASE 3; CATHEPSIN K; COLONY STIMULATING FACTOR 1; GNF 2; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; COLONY STIMULATING FACTOR RECEPTOR; GNF 2 COMPOUND; GNF-2 COMPOUND; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE DESTRUCTION; BONE MARROW; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BONE; BONE MARROW CELL; C-FMS; C-FOS; C57BL MOUSE; CYTOSKELETON; DRUG EFFECT; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETICS; INFLAMMATION; METABOLISM; NF-ΚB; OSTEOCLAST; OSTEOPOROSIS; PATHOLOGY; SIGNAL TRANSDUCTION;

C-FMS; C-FOS; LPS; NF-ΚB; OSTEOPOROSIS;

ANIMALS; BENZAMIDES; BONE AND BONES; BONE MARROW CELLS; BONE RESORPTION; CELL PROLIFERATION; CELL SURVIVAL; CYTOSKELETON; INFLAMMATION; MACROPHAGES; MICE; MICE, INBRED C57BL; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-FOS; PYRIMIDINES; RANK LIGAND; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84897020619     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.0713356     Document Type: Article

References (41)

1. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., Galibert, L. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179.
2. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., Boyle, W. J. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.
3. Wong, B. R., Josien, R., Lee, S. Y., Sauter, B., Li, H. L., Steinman, R. M., Choi, Y. (1997) TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186, 2075-2080.
4. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N., Suda, T. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597-3602.
5. Martin, T. J., Sims, N. A. (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med. 11, 76-81.
6. Boyle, W. J., Simonet, W. S., Lacey, D. L. (2003) Osteoclast differentiation and activation. Nature 423, 337-342.
7. Baron, R., Hesse, E. (2012) Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J. Clin. Endocrinol. Metab. 97, 311-325.
8. Bruzzaniti, A., Baron, R. (2006) Molecular regulation of osteoclast activity. Rev. Endocr. Metab. Disord. 7, 123-139.
9. Teitelbaum, S. L. (2007) Osteoclasts: what do they do and how do they do it? Am. J. Pathol. 170, 427-435.
10. Teitelbaum, S. L., Ross, F. P. (2003) Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4, 638-649.
11. Novack, D. V., Teitelbaum, S. L. (2008) The osteoclast: friend or foe? Ann. Rev. Pathol. 3, 457-484.
12. Asagiri, M., Takayanagi, H. (2007) The molecular understanding of osteoclast differentiation. Bone 40, 251-264.
13. Tanaka, S., Nakamura, K., Takahasi, N., Suda, T. (2005) Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol. Rev. 208, 30-49.
14. Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., Brown, K. D., Leonardi, A., Tran, T., Boyce, B. F., Siebenlist, U. (1997) Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11, 3482-3496.
15. Iotsova, V., Caamano, J., Loy, J., Yang, Y., Lewin, A., Bravo, R. (1997) Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat. Med. 3, 1285-1289.
16. Johnson, R. S., Spiegelman, B. M., Papaioannou, V. (1992) Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71, 577-586.
17. Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J., Wagner, E. F., Mak, T. W., Kodama, T., Taniguchi, T. (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell. 3, 889-901.
18. Wang, Z. Q., Ovitt, C., Grigoriadis, A. E., Mohle-Steinlein, U., Ruther, U., Wagner, E. F. (1992) Bone and haematopoietic defects in mice lacking c-fos. Nature 360, 741-745.
19. Kodama, H., Nose, M., Niida, S., Yamasaki, A. (1991) Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J. Exp. Med. 173, 1291-1294.
20. Wiktor-Jedrzejczak, W., Bartocci, A., Ferrante, A. W., Jr., Ahmed-Ansari, A., Sell, K. W., Pollard, J. W., Stanley, E. R. (1990) Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc. Natl. Acad. Sci. USA 87, 4828-4832.
21. Pixley, F. J., Stanley, E. R. (2004) CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol. 14, 628-638.
22. Ross, F. P. (2006) M-CSF, c-Fms, and signaling in osteoclasts and their precursors. Ann. N. Y. Acad. Sci. 1068, 110-116.
23. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., Lydon, N. B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566.
24. Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., Lydon, N. B. (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139-145.
25. Dewar, A. L., Farrugia, A. N., Condina, M. R., Bik To, L., Hughes, T. P., Vernon-Roberts, B., Zannettino, A. C. (2006) Imatinib as a potential antiresorptive therapy for bone disease. Blood 107, 4334-4337.
26. Paniagua, R. T., Sharpe, O., Ho, P. P., Chan, S. M., Chang, A., Higgins, J. P., Tomooka, B. H., Thomas, F. M., Song, J. J., Goodman, S. B., Lee, D. M., Genovese, M. C., Utz, P. J., Steinman, L., Robinson, W. H. (2006) Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 116, 2633-2642.
27. Adrian, F. J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P., Mestan, J., Fabbro, D., Gray, N. S. (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2, 95-102.
28. Kim, H. J., Hong, J. M., Yoon, K. A., Kim, N., Cho, D. W., Choi, J. Y., Lee, I. K., Kim, S. Y. (2012) Early growth response 2 negatively modulates osteoclast differentiation through upregulation of Id helix-loophelix proteins. Bone 51, 643-650.
29. Kim, H. J., Zhao, H., Kitaura, H., Bhattacharyya, S., Brewer, J. A., Muglia, L. J., Ross, F. P., Teitelbaum, S. L. (2006) Glucocorticoids suppress bone formation via the osteoclast. J. Clin. Invest. 116, 2152-2160.
30. McHugh, K. P., Hodivala-Dilke, K., Zheng, M. H., Namba, N., Lam, J., Novack, D., Feng, X., Ross, F. P., Hynes, R. O., Teitelbaum, S. L. (2000) Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest. 105, 433-440.
31. Ishida, A., Fujita, N., Kitazawa, R., Tsuruo, T. (2002) Transforming growth factor-β induces expression of receptor activator of NF-κ B ligand in vascular endothelial cells derived from bone. J. Biol. Chem. 277, 26217-26224.
32. Matsuo, K., Galson, D. L., Zhao, C., Peng, L., Laplace, C., Wang, K. Z., Bachler, M. A., Amano, H., Aburatani, H., Ishikawa, H., Wagner, E. F. (2004) Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J. Biol. Chem. 279, 26475-26480.
33. Garcia-Gomez, A., Ocio, E. M., Crusoe, E., Santamaria, C., Hernandez-Campo, P., Blanco, J. F., Sanchez-Guijo, F. M., Hernandez-Iglesias, T., Brinon, J. G., Fisac-Herrero, R. M., Lee, F. Y., Pandiella, A., San Miguel, J. F., Garayoa, M. (2012) Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PloS One 7, e34914.
34. Tai, Y. T., Chang, B. Y., Kong, S. Y., Fulciniti, M., Yang, G., Calle, Y., Hu, Y., Lin, J., Zhao, J. J., Cagnetta, A., Cea, M., Sellitto, M. A., Zhong, M. Y., Wang, Q., Acharya, C., Carrasco, D. R., Buggy, J. J., Elias, L., Treon, S. P., Matsui, W., Richardson, P., Munshi, N. C., Anderson, K. C. (2012) Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120, 1877-1887.
35. Yamashita, T., Yao, Z., Li, F., Zhang, Q., Badell, I. R., Schwarz, E. M., Takeshita, S., Wagner, E. F., Noda, M., Matsuo, K., Xing, L., Boyce, B. F. (2007) NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J. Biol. Chem. 282, 18245-18253.
36. [No authors listed] (2004) Abstracts of the 26th Annual Meeting of the American Society for Bone and Mineral Research. October 1-5, 2004, Seattle, Washington, USA. J. Bone Miner. Res. 19 (Suppl. 1), S2-S543.
37. Wolf, A. M., Wolf, D., Rumpold, H., Ludwiczek, S., Enrich, B., Gastl, G., Weiss, G., Tilg, H. (2005) The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc. Natl. Acad. Sci. USA 102, 13622-13627.
38. Dewar, A. L., Cambareri, A. C., Zannettino, A. C., Miller, B. L., Doherty, K. V., Hughes, T. P., Lyons, A. B. (2005) Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105, 3127-3132.
39. Faccio, R., Zou, W., Colaianni, G., Teitelbaum, S. L., Ross, F. P. (2003) High dose M-CSF partially rescues the Dap12-/-osteoclast phenotype. J. Cell. Biochem. 90, 871-883.
40. Hong, J. M., Teitelbaum, S. L., Kim, T. H., Ross, F. P., Kim, S. Y., Kim, H. J. (2011) Calpain-6, a target molecule of glucocorticoids, regulates osteoclastic bone resorption via cytoskeletal organization and microtubule acetylation. J. Bone Miner. Res. 26, 657-665.
41. Kitaura, H., Zhou, P., Kim, H. J., Novack, D. V., Ross, F. P., Teitelbaum, S. L. (2005) M-CSF mediates TNF-induced inflammatory osteolysis. J. Clin. Invest. 115, 3418-3427.